Physician profile
Mitchell Wong
NPI 1184150138
$12,864.27
in general payments reported to CMS, 2019-2025
68 companies · $1,946 in 2025
The $1,946 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $1,073 · 2021: $2,552 · 2022: $2,285 · 2023: $3,044 · 2024: $1,835 · 2025: $1,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,824.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,688.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,409.79 | 2020-2025 | Farxiga, Airsupra, Fasenra |
| Abbvie INC. | $1,349.99 | 2020-2025 | Ubrelvy, Synthroid, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,038.60 | 2020-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $910.80 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Amarin Pharma, INC. | $705.91 | 2019-2023 | |
| Stryker Corporation | $369.88 | 2022-2023 | Mako |
| Glaxosmithkline, LLC. | $321.49 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $321.41 | 2020-2025 | Repatha, Otezla, Repatha |
| Antares Pharma, INC. | $292.53 | 2020-2024 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $285.28 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.65 | 2020-2025 | Xifaxan |
| Corium, LLC | $260.02 | 2022-2025 | Azstarys |
| Medtronic, INC. | $255.44 | 2023-2024 | Intellis Adaptivestim, Vanta Adaptivestim |
| Amneal Pharmaceuticals LLC | $253.39 | 2020-2025 | Unithroid |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.